251 related articles for article (PubMed ID: 31586799)
21. Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
Bsteh G; Hegen H; Teuchner B; Amprosi M; Berek K; Ladstätter F; Wurth S; Auer M; Di Pauli F; Deisenhammer F; Berger T
Mult Scler; 2019 Feb; 25(2):196-203. PubMed ID: 29095097
[TBL] [Abstract][Full Text] [Related]
22. The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis.
Yaldizli Ö; Penner IK; Yonekawa T; Naegelin Y; Kuhle J; Pardini M; Chard DT; Stippich C; Kira JI; Bendfeldt K; Amann M; Radue EW; Kappos L; Sprenger T
Eur J Neurol; 2016 Mar; 23(3):510-9. PubMed ID: 26699999
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of cognitive impairment among Hungarian patients with relapsing-remitting multiple sclerosis and clinically isolated syndrome.
Sandi D; Biernacki T; Szekeres D; Füvesi J; Kincses ZT; Rózsa C; Mátyás K; Kása K; Matolcsi J; Zboznovits D; Burány Z; Langane É; Vécsei L; Bencsik K
Mult Scler Relat Disord; 2017 Oct; 17():57-62. PubMed ID: 29055476
[TBL] [Abstract][Full Text] [Related]
24. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
[TBL] [Abstract][Full Text] [Related]
25. Is impairment of facial emotion recognition independent of cognitive dysfunction in multiple sclerosis?
Sever Aktuna YS; Koskderelioglu A; Eskut N; Aktuna A
Neurol Sci; 2024 Jun; 45(6):2791-2800. PubMed ID: 38246940
[TBL] [Abstract][Full Text] [Related]
26. Demographic features, behavioral measures, and clinical factors as predictors of cognitive function in patients with multiple sclerosis.
Alirezaei M; Forouzannia SM; Yarahmadi P; Sahraian MA; Owji M; Bidadian M; Ghadiri F; Naser Moghadasi A
Mult Scler Relat Disord; 2021 Apr; 49():102758. PubMed ID: 33567391
[TBL] [Abstract][Full Text] [Related]
27. The Expanded Disability Status Scale Score and Demographic Indexes Are Correlated with the Severity of Cognitive Impairment in Multiple Sclerosis Patients.
Sadigh-Eteghad S; Abbasi Garravnd N; Feizollahi M; Talebi M
J Clin Neurol; 2021 Jan; 17(1):113-120. PubMed ID: 33480206
[TBL] [Abstract][Full Text] [Related]
28. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.
Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH
Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979
[TBL] [Abstract][Full Text] [Related]
29. The Italian validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the application of the Cognitive Impairment Index scoring procedure in MS patients.
Argento O; Incerti CC; Quartuccio ME; Magistrale G; Francia A; Caltagirone C; Pisani V; Nocentini U
Neurol Sci; 2018 Jul; 39(7):1237-1244. PubMed ID: 29704074
[TBL] [Abstract][Full Text] [Related]
30. A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.
López-Góngora M; Querol L; Escartín A
BMC Neurol; 2015 Mar; 15():40. PubMed ID: 25886168
[TBL] [Abstract][Full Text] [Related]
31. Association of cognitive impairment and quality of life in patients with multiple sclerosis: A cross-sectional study.
Nabizadeh F; Balabandian M; Rostami MR; Owji M; Sahraian MA; Bidadian M; Ghadiri F; Rezaeimanesh N; Moghadasi AN
Curr J Neurol; 2022 Jul; 21(3):144-150. PubMed ID: 38011341
[No Abstract] [Full Text] [Related]
32. Is there a correlation between dyslipidemia and cognitive impairment in patients with multiple sclerosis?
Andaloro A; Russo M; Pastura C; Sessa E; Calatozzo P; Maggio MG; Bramanti P
Int J Neurosci; 2022 Feb; 132(2):201-206. PubMed ID: 32767908
[No Abstract] [Full Text] [Related]
33. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.
Ruano L; Portaccio E; Goretti B; Niccolai C; Severo M; Patti F; Cilia S; Gallo P; Grossi P; Ghezzi A; Roscio M; Mattioli F; Stampatori C; Trojano M; Viterbo RG; Amato MP
Mult Scler; 2017 Aug; 23(9):1258-1267. PubMed ID: 27738090
[TBL] [Abstract][Full Text] [Related]
34. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
35. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA
Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273
[TBL] [Abstract][Full Text] [Related]
36. Role of Demographic and Clinical Factors in Cognitive Functioning of Persons with Relapsing-Remitting and Progressive Multiple Sclerosis.
Costa SL; DeLuca J; Sandroff BM; Goverover Y; Chiaravalloti ND
J Int Neuropsychol Soc; 2018 Feb; 24(2):139-146. PubMed ID: 28830576
[TBL] [Abstract][Full Text] [Related]
37. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
[TBL] [Abstract][Full Text] [Related]
38. Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery.
Cinar BP; Kösehasanoğulları G; Yigit P; Ozakbas S
Neurol Sci; 2017 Feb; 38(2):337-342. PubMed ID: 27885448
[TBL] [Abstract][Full Text] [Related]
39. Validation of the French version of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).
Maubeuge N; Deloire MSA; Brochet B; Ehrlé N; Charré-Morin J; Saubusse A; Ruet A;
Mult Scler Relat Disord; 2021 Feb; 48():102692. PubMed ID: 33352358
[TBL] [Abstract][Full Text] [Related]
40. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
